Biomerica vs Icecure Medical
Biomerica is the larger business, with $4.5m of revenue in fiscal 2026 against $3.4m for Icecure Medical (1.3 times as much). Icecure Medical grew faster (2.7% against -16.2%). Biomerica kept more of each dollar of sales as profit: a net margin of -84.8% against -445.6%. Biomerica carries less debt relative to equity (0.0% against 0.1%).
| Latest fiscal year | BiomericaBMRA, 2026 | Icecure MedicalICCM, 2025 |
|---|---|---|
| Revenue | $4.5m | $3.4m |
| Revenue growth | -16.2% | 2.7% |
| Net income | −$3.8m | −$15.1m |
| Operating margin | -119.5% | -446.7% |
| Net margin | -84.8% | -445.6% |
| Return on equity | -112.1% | -188.8% |
| Free cash flow | −$3.4m | −$14.6m |
| Cash | $1.3m | $8.9m |
| Total debt | $0 | $13,000 |
| Debt to equity | 0.0% | 0.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 54 | — |
| Market value | $8.0m | $57.0m |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | — |
| Insider trades, 12 months | 5 buys, 0 sales | 0 buys, 0 sales |